Quest Diagnostics brings a $29 biological-age report to the U.S.—no extra blood draw
Quest Diagnostics (DGX) added Humanity Health's $29 Biological Age analysis to select health profile tests on questhealth.com. Customers can access the report via Quest's 2,000 U.S. centers. The model, trained on 306,000 UK Biobank participants, estimates biological age and its contributors. Quest cannot refund third-party reports.
How this was made
The 30-second read
Why it matters
The service could attract health‑conscious consumers and generate incremental revenue, though the financial impact is expected to be modest.
Market read
A new consumer‑focused health product from a major diagnostics firm, modest relevance for traders watching DGX.
What to watch
Potential regulatory scrutiny of wellness claims and competition from other at‑home testing providers.
Background
Quest Diagnostics (DGX) announced the addition of Humanity Health’s Biological Age analysis to its consumer health platform, questhealth.com, priced at $29 with no extra blood draw.
Ticker impact
Quest Diagnostics launched a $29 add‑on Biological Age report on its consumer platform, a new revenue‑generating service.
Small upside pressure if market views the service as a growth catalyst.
The launch is a first‑time offering but limited in scale and price, likely affecting only niche consumer health segment.
Market effects
Adds a consumer‑health service line to the diagnostics sector, modestly differentiating Quest from peers.
U.S. consumer health market sees a new wellness product, limited broader impact.
Limited to U.S. market; no immediate global effect.
Counterpoint
The $29 price point may be too low to generate meaningful revenue, and consumer uptake could be limited.
Key entities
- CompanyQuest Diagnostics
U.S. diagnostics provider launching the new add‑on.
- CompanyHumanity Health
Provider of the Biological Age model partnered with Quest.
